Train Babcock Advisors LLC decreased its stake in shares of Zoetis Inc. (NYSE:ZTS) by 1.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 77,915 shares of the company’s stock after selling 975 shares during the period. Zoetis accounts for 2.8% of Train Babcock Advisors LLC’s investment portfolio, making the stock its 11th biggest position. Train Babcock Advisors LLC’s holdings in Zoetis were worth $4,968,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently added to or reduced their stakes in the business. BlackRock Inc. increased its position in Zoetis by 3.9% during the second quarter. BlackRock Inc. now owns 37,495,299 shares of the company’s stock worth $2,338,957,000 after buying an additional 1,412,829 shares in the last quarter. Vanguard Group Inc. increased its position in Zoetis by 2.8% during the second quarter. Vanguard Group Inc. now owns 33,654,686 shares of the company’s stock worth $2,099,379,000 after buying an additional 910,265 shares in the last quarter. Alliancebernstein L.P. increased its position in Zoetis by 55.4% during the second quarter. Alliancebernstein L.P. now owns 10,370,388 shares of the company’s stock worth $646,905,000 after buying an additional 3,695,449 shares in the last quarter. American Century Companies Inc. increased its position in Zoetis by 7.2% during the second quarter. American Century Companies Inc. now owns 6,207,974 shares of the company’s stock worth $387,253,000 after buying an additional 417,455 shares in the last quarter. Finally, Janus Henderson Group PLC increased its position in Zoetis by 7,717.4% during the second quarter. Janus Henderson Group PLC now owns 5,809,086 shares of the company’s stock worth $362,372,000 after buying an additional 5,734,776 shares in the last quarter. 92.90% of the stock is owned by institutional investors.

Shares of Zoetis Inc. (ZTS) traded up $1.02 during trading on Tuesday, reaching $69.71. The company had a trading volume of 3,884,094 shares, compared to its average volume of 2,410,000. Zoetis Inc. has a 52-week low of $48.24 and a 52-week high of $70.48. The firm has a market capitalization of $33,580.00, a PE ratio of 31.51, a P/E/G ratio of 2.02 and a beta of 1.02. The company has a quick ratio of 1.95, a current ratio of 2.80 and a debt-to-equity ratio of 2.45.

Zoetis (NYSE:ZTS) last issued its earnings results on Thursday, November 2nd. The company reported $0.65 earnings per share for the quarter, beating the Zacks’ consensus estimate of $0.63 by $0.02. The firm had revenue of $1.35 billion for the quarter, compared to analysts’ expectations of $1.32 billion. Zoetis had a return on equity of 62.39% and a net margin of 18.29%. The firm’s revenue for the quarter was up 8.5% compared to the same quarter last year. During the same quarter last year, the firm earned $0.52 earnings per share. analysts predict that Zoetis Inc. will post 2.35 EPS for the current fiscal year.

The business also recently disclosed a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Thursday, November 9th will be paid a dividend of $0.105 per share. This represents a $0.42 dividend on an annualized basis and a dividend yield of 0.60%. The ex-dividend date of this dividend is Wednesday, November 8th. Zoetis’s dividend payout ratio is presently 22.11%.

ILLEGAL ACTIVITY WARNING: This news story was published by Watch List News and is the sole property of of Watch List News. If you are accessing this news story on another domain, it was stolen and reposted in violation of United States & international trademark and copyright law. The original version of this news story can be viewed at https://www.watchlistnews.com/train-babcock-advisors-llc-sells-975-shares-of-zoetis-inc-zts/1685867.html.

ZTS has been the topic of several analyst reports. BMO Capital Markets set a $65.00 price objective on Zoetis and gave the stock a “hold” rating in a report on Wednesday, October 25th. BidaskClub upgraded Zoetis from a “buy” rating to a “strong-buy” rating in a report on Tuesday, September 12th. Cantor Fitzgerald restated a “buy” rating and set a $75.00 price objective on shares of Zoetis in a report on Tuesday, October 24th. Deutsche Bank AG restated a “buy” rating and set a $65.00 price objective (up previously from $62.00) on shares of Zoetis in a report on Monday, July 17th. Finally, Stifel Nicolaus restated a “buy” rating and set a $65.00 price objective on shares of Zoetis in a report on Friday, September 1st. Two research analysts have rated the stock with a sell rating, five have issued a hold rating and eleven have given a buy rating to the company. Zoetis presently has an average rating of “Buy” and a consensus target price of $67.06.

About Zoetis

Zoetis Inc is engaged in the discovery, development, manufacture and commercialization of animal health medicines and vaccines, with a focus on both livestock and companion animals. The Company has a business, commercializing products across eight core species: cattle, swine, poultry, sheep and fish (collectively, livestock) and dogs, cats and horses (collectively, companion animals), and within five product categories: anti-infectives, vaccines, parasiticides, medicated feed additives and other pharmaceuticals.

Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc. (NYSE:ZTS).

Institutional Ownership by Quarter for Zoetis (NYSE:ZTS)

Receive News & Ratings for Zoetis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.